Amicus Therapeutics - Stock Price History | FOLD
Historical daily share price chart and data for Amicus Therapeutics since 2023 adjusted for splits. The latest closing stock price for Amicus Therapeutics as of January 27, 2023 is 12.83.
- The all-time high Amicus Therapeutics stock closing price was 24.89 on December 22, 2020.
- The Amicus Therapeutics 52-week high stock price is 13.62, which is 6.2% above the current share price.
- The Amicus Therapeutics 52-week low stock price is 5.91, which is 53.9% below the current share price.
- The average Amicus Therapeutics stock price for the last 52 weeks is 10.19.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Amicus Therapeutics Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2022 |
10.0169 |
12.1100 |
12.7500 |
6.2300 |
12.2100 |
5.71% |
| 2021 |
11.6151 |
21.7800 |
23.8600 |
8.7100 |
11.5500 |
-49.98% |
| 2020 |
14.2237 |
9.5500 |
24.8900 |
6.6300 |
23.0900 |
137.06% |
| 2019 |
11.2103 |
10.0400 |
14.4000 |
7.4800 |
9.7400 |
1.67% |
| 2018 |
13.8221 |
15.1600 |
17.1200 |
8.3800 |
9.5800 |
-33.43% |
| 2017 |
10.3500 |
5.1300 |
16.2400 |
5.1300 |
14.3900 |
189.54% |
| 2016 |
6.9360 |
9.0300 |
9.3500 |
4.5300 |
4.9700 |
-48.76% |
| 2015 |
11.4110 |
8.6100 |
18.2300 |
5.9500 |
9.7000 |
16.59% |
| 2014 |
4.2658 |
2.4100 |
8.6100 |
1.8200 |
8.3200 |
254.04% |
| 2013 |
2.7800 |
2.8400 |
4.2200 |
1.9700 |
2.3500 |
-12.31% |
| 2012 |
5.2648 |
3.5700 |
6.8800 |
2.5300 |
2.6800 |
-22.09% |
| 2011 |
5.3292 |
4.5600 |
7.9400 |
2.1000 |
3.4400 |
-26.81% |
| 2010 |
3.4267 |
3.8400 |
4.8000 |
1.9500 |
4.7000 |
18.39% |
| 2009 |
7.9094 |
8.0000 |
12.2700 |
3.3600 |
3.9700 |
-50.25% |
| 2008 |
11.2884 |
10.3400 |
17.9500 |
7.5000 |
7.9800 |
-25.77% |
| 2007 |
13.8496 |
14.4300 |
18.0400 |
9.5400 |
10.7500 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.700B |
$0.306B |
|
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
|
